Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy
2013-003272-12Phase 2Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Mar 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of aflibercept in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Moorfields Eye Hospital. Primary endpoint: Best corrected visual acuity change at 52 weeks. Started Mar 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2013-003272-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003272-12.